BR112022003826A2 - Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit - Google Patents

Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit

Info

Publication number
BR112022003826A2
BR112022003826A2 BR112022003826A BR112022003826A BR112022003826A2 BR 112022003826 A2 BR112022003826 A2 BR 112022003826A2 BR 112022003826 A BR112022003826 A BR 112022003826A BR 112022003826 A BR112022003826 A BR 112022003826A BR 112022003826 A2 BR112022003826 A2 BR 112022003826A2
Authority
BR
Brazil
Prior art keywords
methods
cell population
kit
dopamine neurons
composition
Prior art date
Application number
BR112022003826A
Other languages
English (en)
Inventor
Lorenz Studer
Yeon Koo So
Stefan Irion
Taewan Kim
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112022003826A2 publication Critical patent/BR112022003826A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit. a presente revelação fornece métodos para gerar neurônios de dopamina do mesencéfalo (mdas) e precursores dos mesmos, mdas e precursores dos mesmos gerados por tais métodos e composições que compreendem tais células e usos das mesmas para prevenir e/ou tratar distúrbios neurológicos. a presente revelação fornece ainda métodos para isolar mdas e precursores dos mesmos de uma população celular com o uso de marcadores de superfície inovadores.
BR112022003826A 2019-08-29 2020-08-31 Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit BR112022003826A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893674P 2019-08-29 2019-08-29
PCT/US2020/048733 WO2021042027A1 (en) 2019-08-29 2020-08-31 Methods of generating and isolating midbrain dopamine neurons

Publications (1)

Publication Number Publication Date
BR112022003826A2 true BR112022003826A2 (pt) 2022-05-31

Family

ID=74686069

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003826A BR112022003826A2 (pt) 2019-08-29 2020-08-31 Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit

Country Status (12)

Country Link
US (1) US20220177835A1 (pt)
EP (1) EP4021477A4 (pt)
JP (1) JP2022546482A (pt)
KR (1) KR20220051388A (pt)
CN (1) CN114650836A (pt)
AU (1) AU2020336221A1 (pt)
BR (1) BR112022003826A2 (pt)
CA (1) CA3152522A1 (pt)
IL (1) IL290930A (pt)
MX (1) MX2022002532A (pt)
WO (1) WO2021042027A1 (pt)
ZA (1) ZA202202994B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3792346B1 (en) 2019-09-13 2023-07-26 Miltenyi Biotec B.V. & Co. KG Method for the generation of a cell composition of ventral midbrain dopaminergic progenitor cells
WO2023285514A1 (en) 2021-07-14 2023-01-19 Novo Nordisk A/S Method for providing a cell population enriched in neurons and precursors thereof
CN115354028B (zh) * 2021-10-28 2023-05-23 中国科学院动物研究所 一种中脑多巴胺细胞群、其制造方法以及用途
WO2024019800A1 (en) * 2022-07-21 2024-01-25 Trailhead Biosystems Inc. Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells
CN117838835A (zh) * 2024-02-01 2024-04-09 暨南大学 成纤维细胞生长因子17蛋白和/或其激活剂在制备治疗阿尔兹海默病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632679B2 (en) * 2002-07-16 2009-12-15 The Trustees Of Columbia University In The City Of New York Systems and methods for screening for modulators of neural differentiation
JP6090937B2 (ja) * 2011-07-27 2017-03-08 国立大学法人京都大学 新規ドーパミン産生神経前駆細胞マーカー
ES2721440T3 (es) * 2013-09-05 2019-07-31 Univ Kyoto Nuevo método para inducir células precursoras neurales productoras de dopamina
CN107438669B (zh) * 2015-04-09 2022-09-27 拜奥拉米那公司 用于治疗神经退行性疾病的干细胞衍生多巴胺能细胞的生产方法和组合物
WO2016196661A1 (en) * 2015-06-01 2016-12-08 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (mda) neurons
EP4328301A3 (en) * 2016-08-16 2024-06-19 FUJIFILM Cellular Dynamics, Inc. Methods for differentiating pluripotent cells

Also Published As

Publication number Publication date
CA3152522A1 (en) 2021-03-04
US20220177835A1 (en) 2022-06-09
KR20220051388A (ko) 2022-04-26
IL290930A (en) 2022-04-01
EP4021477A1 (en) 2022-07-06
EP4021477A4 (en) 2023-12-13
ZA202202994B (en) 2022-12-21
WO2021042027A1 (en) 2021-03-04
JP2022546482A (ja) 2022-11-04
AU2020336221A1 (en) 2022-04-07
MX2022002532A (es) 2022-06-16
CN114650836A (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
BR112022003826A2 (pt) Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit
ECSP22029193A (es) Aminas bicíclicas como inhibidoras de la cdk2
CO2021009695A2 (es) Conjugados de il-2 y métodos de uso de este
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
BR112022002991A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CL2018001845A1 (es) Moduladores de la 5'-nucleotidasa, ecto y su uso
CL2020001133A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664)
CO6602158A2 (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
UY38476A (es) Inhibidores de arg1 y/o arg2
BR112017021536A2 (pt) composições e métodos para o condicionamento não mieloablativo
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
UY27906A1 (es) Inhibidores de quinasas
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
BR112016029846A2 (pt) ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo?
BRPI0512864A (pt) composições e métodos para o tratamento de condições e desordens oculares
BR112022002378A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
CL2020002271A1 (es) Inhibidores de la arginasa
BR112019021857A2 (pt) Métodos e composições de célula t aperfeiçoada
BR112017010495A2 (pt) tratamentos para envenenamento e composições farmacêuticas, sistemas e kits relacionados
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112022005711A2 (pt) Métodos e composições para tratar uma doença ou transtorno